Good to see a close above here, volume looks thin as people hold...

Good to see a close above here, volume looks thin as people hold for news so we should see a breakout to test the $1.60 from the IPO early days before any news.

$3-4 is only ~$1600-$220m Mcap! Still cray cheap for how close we are/ease of getting a drug to market, listening to the conference link Jason seemed very confident of the upcoming news being able to enable us to move onto further stages. He would already know the results and the report would just be fine tuned at the moment and hence why he is out promoting the company.

Amazing to see that they still have $10m from the IPO, the company really does run on an oily rag. Even if we did get ourselves fully funded with $20-30m more for the P3 trial it would be small in dilution and heavily subscribed as it would be de risked significantly.